How does Keytruda (pembrolizumab) work in the body?
Keytruda is an immune checkpoint inhibitor. Its main target is PD-1 (programmed death-1) on T cells. Normally, when PD-1 is engaged by its ligands, it turns down T-cell activity. Keytruda blocks PD-1, which helps restore T-cell responses against cancer cells [1].
What does the “mechanism of action” storyline look like in a video?
A typical visual “mechanism” sequence goes like this:
1. Cancer cells can display PD-L1 (and related signals) that interact with PD-1 on T cells.
2. That PD-1 signaling puts the T cell into a more “off” state.
3. Keytruda binds to PD-1 and blocks that inhibitory signal.
4. T cells regain activity and can better recognize and attack tumor cells [1].
Why does blocking PD-1 help cancer treatment?
By preventing the PD-1 inhibitory pathway, Keytruda reduces the cancer’s ability to suppress the immune system. That can allow T cells to proliferate and function more effectively against the tumor [1].
What kinds of cancers is Keytruda used for (context for MOA videos)?
Keytruda has approvals across several cancer types, including melanoma, non-small cell lung cancer, urothelial cancer, and others, with indications that depend on biomarkers and prior treatments. MOA videos often pair the PD-1 blockade concept with “T-cell reactivation” visuals to explain why it can work across multiple tumors [1].
Can you use a Keytruda mechanism-of-action video for patient education?
Yes. For patient-facing videos, the most accurate framing is that Keytruda helps “take the brakes off” T cells by blocking PD-1, rather than directly killing cancer cells itself. The core concept in the animation should stay focused on PD-1 blocking and immune reactivation [1].
Sources
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/